TCM
Tang Capital Management Portfolio holdings
AUM
$2.02B
1-Year Est. Return
102.23%
This Fund
S&P 500
1 Year Est. Return
+102.23%
AUM
$2.02B
AUM Growth
-$573M
(-22%)
Holding
201
Top Buys
| 1 | +$58.1M | |
| 2 | +$22.2M | |
| 3 | +$20.3M | |
| 4 |
BioNTech
BNTX
|
+$20.1M |
| 5 |
ANI Pharmaceuticals
ANIP
|
+$14.2M |
Top Sells
| 1 | +$94.5M | |
| 2 | +$56.5M | |
| 3 | +$42.1M | |
| 4 |
Vera Therapeutics
VERA
|
+$39.2M |
| 5 |
Nike
NKE
|
+$36.2M |
Sector Composition
| 1 | Healthcare | 96.95% |
| 2 | Technology | 1.18% |
| 3 | Communication Services | 0.76% |
| 4 | Real Estate | 0.1% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$3.81B
| $17.6M | 0.87% |
500,000
-370,000
|
|
||
27
Atea Pharmaceuticals
AVIR
$460M
| $17.2M | 0.85% |
4,814,700
-11,500
|
|
||
28
Stoke Therapeutics
STOK
$2.03B
| $15.9M | 0.78% |
500,000
|
|
||
29
IDEAYA Biosciences
IDYA
$2.91B
| $15.6M | 0.77% |
450,000
+50,000
|
|
||
30
Meta Platforms (Facebook)
META
$1.63T
| $15.4M | 0.76% |
23,331
-2,677
|
|
||
31
GSK
GSK
$109B
| $14.7M | 0.73% |
300,000
-100,000
|
|
||
32
Journey Medical
DERM
$258M
| $14.3M | 0.71% |
1,854,596
|
|
||
|
LENZ
33
LENZ Therapeutics
LENZ
$365M
| $13.8M | 0.68% |
865,169
-32,447
|
|
||
34
Vaxcyte
PCVX
$8.53B
| $12.7M | 0.63% |
275,000
-25,000
|
|
||
35
Dianthus Therapeutics
DNTH
$2.82B
| $10.9M | 0.54% |
264,692
|
|
||
36
Harmony Biosciences
HRMY
$1.64B
| $10.9M | 0.54% |
290,292
+9,092
|
|
||
37
Bristol-Myers Squibb
BMY
$123B
| $10.8M | 0.53% |
+200,000
|
|
||
38
Insmed
INSM
$30.2B
| $10.4M | 0.52% |
60,000
-140,000
|
|
||
|
CBIO
39
Crescent Biopharma
CBIO
$367M
| $10.3M | 0.51% |
872,398
+192,574
|
|
||
40
Wave Life Sciences
WVE
$2.44B
| $10.2M | 0.5% |
+600,000
|
|
||
41
Teladoc Health
TDOC
$902M
| $9.8M | 0.48% |
1,400,000
|
|
||
|
DVAX
42
DELISTED
Dynavax Technologies
DVAX
| $8.56M | 0.42% |
556,359
-1,393,141
|
|
||
43
Evolus
EOLS
$358M
| $8.28M | 0.41% |
1,245,692
-4,242,607
|
|
||
44
Verastem
VSTM
$481M
| $8.26M | 0.41% |
1,069,810
+280,000
|
|
||
45
UroGen Pharma
URGN
$958M
| $8.2M | 0.4% |
350,000
-650,000
|
|
||
46
Heron Therapeutics
HRTX
$177M
| $8.13M | 0.4% |
6,250,000
+2,800,000
|
|
||
47
Acadia Pharmaceuticals
ACAD
$3.78B
| $8.01M | 0.4% |
300,000
-1,200,000
|
|
||
48
Altimmune
ALT
$443M
| $7.69M | 0.38% |
2,131,307
|
|
||
49
Sarepta Therapeutics
SRPT
$1.75B
| $7.52M | 0.37% |
349,220
-250,780
|
|
||
50
Pliant Therapeutics
PLRX
$81.7M
| $7.49M | 0.37% |
6,143,132
+139,686
|
|